Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors

Fig. 2

Changes in CD16-positive natural killer (NK) cells. Time-course of circulating CD16-positive NK cells (CD3−CD56+CD16+) after DS-8895a treatment in a) Cycle 1 of Step 1 and b) Cycle 1 of Step 2, and c) the ratio of CD3−CD56+CD137+ cells to CD3−CD56+CD16+ cells in Cycle 1 of Step 2

Back to article page